A controlled trial of sildenafil in advanced idiopathic pulmonary fibrosis

DOI: 10.1056/nejmoa1002110
New England Journal of Medicine, 2010, 363, 620-8.

#	Paper	IF	Citations
496	Sildenafil in idiopathic pulmonary fibrosis. *New England Journal of Medicine*, **2010**, 363, 2170; author reply 2170-1	59.2	4
495	Emerging potential treatments: new hope for idiopathic pulmonary fibrosis patients?. *European Respiratory Review*, **2011**, 20, 201-7	9.8	4
494	Update in diffuse parenchymal lung disease 2010. *American Journal of Respiratory and Critical Care Medicine*, **2011**, 183, 1316-21	10.2	2
493	Les maladies interstitielles pulmonaires. **2011**, 3, 17-24		1
492	Hypertension pulmonaire et fibrose pulmonaire idiopathique. **2011**, 3, 531		
491	Interstitial lung disease: the initial approach. **2011**, 95, 1071-93		7
490	An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. *American Journal of Respiratory and Critical Care Medicine*, **2011**, 183, 788-824	10.2	4665
489	New insights into the pathogenesis and treatment of idiopathic pulmonary fibrosis. **2011**, 71, 981-1001		43
488	[Innovative therapeutics for idiopathic pulmonary fibrosis]. **2011**, 40, 1100-12		2
487	Pulmonary hypertension due to chronic lung disease: updated Recommendations of the Cologne Consensus Conference 2011. **2011**, 154 Suppl 1, S45-53		48
486	Idiopathic pulmonary fibrosis. **2011**, 378, 1949-61		1196
485	Effect and safety of mycophenolate mofetil in idiopathic pulmonary fibrosis. **2011**, 2011, 849035		9
484	Clinical trials in idiopathic pulmonary fibrosis: update and perspectives. **2011**, 1, 1669-1680		
483	Comprehensive care of the patient with idiopathic pulmonary fibrosis. **2011**, 17, 348-54		63
482	Pulmonary Hypertension in Interstitial Lung Disease. **2011**, 18, 222-229		
481	The pulmonary arteries, idiopathic pulmonary fibrosis, and lung transplantation: deciphering the connection. *Chest*, **2011**, 139, 741-743	5.3	1
480	A case of progressive lung fibrosis. **2011**, 341, 428-30		

479	Effects of inhaled nitric oxide at rest and during exercise in idiopathic pulmonary fibrosis. **2011**, 110, 638-45		32
478	Management of idiopathic pulmonary fibrosis. **2011**, 341, 450-3		7
477	Year in review 2010: interstitial lung diseases, acute lung injury, sleep, physiology, imaging, bronchoscopic intervention and lung cancer. **2011**, 16, 553-63		
476	Idiopathic pulmonary fibrosis-related pulmonary hypertension; an exercising diagnosis?. **2011**, 16, 381-3		1
475	An investigator-driven study of everolimus in surgical lung biopsy confirmed idiopathic pulmonary fibrosis. **2011**, 16, 776-83		70
474	Novel therapeutic approaches for pulmonary fibrosis. **2011**, 163, 141-72		140
473	[Treatment of pulmonary fibrosis. New substances and new interventions]. **2011**, 52, 1422-8		5
472	Idiopathic pulmonary fibrosis: treatment update. *Advances in Therapy*, **2011**, 28, 986-99	4.1	20
471	Clinical year in review I: interstitial lung disease, occupational and environmental lung disease, education of residents and fellows, and pediatrics. **2011**, 8, 389-97		2
470	[Interstitial lung disease]. **2011**, 136, 1191-3		
469	Current and Future Therapies for Idiopathic Pulmonary Fibrosis. **2011**, 18, 257-264		2
468	Pirfenidone treatment of idiopathic pulmonary fibrosis. **2011**, 7, 39-47		14
467	Pulmonary hypertension in idiopathic pulmonary fibrosis: a review. **2011**, 82, 294-304		52
466	Clinical course and prediction of survival in idiopathic pulmonary fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2011**, 183, 431-40	10.2	998
465	Lung transplantation for pulmonary hypertension. **2011**, 1, 182-91		31
464	Pulmonary hypertension secondary to interstitial lung disease. **2011**, 5, 179-89		16
463	Sildenafil for COPD: a randomized crossover trial. **2012**, 9, 211-2		2
462	Severe pulmonary hypertension in idiopathic nonspecific interstitial pneumonia. **2012**, 2, 101-6		13

461	Development and preclinical efficacy of novel transforming growth factor-β1 short interfering RNAs for pulmonary fibrosis. **2012**, 46, 397-406		37
460	Interstitial lung abnormalities and reduced exercise capacity. *American Journal of Respiratory and Critical Care Medicine*, **2012**, 185, 756-62	10.2	74
459	Pulmonary Hypertension Complicating Interstitial and Granulomatous Lung Diseases. **2012**, 178-198		1
458	Acute exacerbations and pulmonary hypertension in advanced idiopathic pulmonary fibrosis. *European Respiratory Journal*, **2012**, 40, 93-100	13.6	112
457	Pulmonary hypertension in parenchymal lung disease. **2012**, 2012, 684781		4
456	Clinical trials and tribulations--lessons from pulmonary fibrosis. **2012**, 105, 1043-7		14
455	Patient-reported outcomes in idiopathic pulmonary fibrosis research. *Chest*, **2012**, 142, 291-297	5.3	28
454	Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. **2012**, 157, 398-406		138
453	Idiopathic pulmonary fibrosis: new evidence and an improved standard of care in 2012. **2012**, 380, 699-701		12
452	Pulmonary hypertension in idiopathic pulmonary fibrosis: epidemiology, diagnosis and therapeutic implications. **2012**, 1, 233-242		7
451	Clinical trials in idiopathic pulmonary fibrosis: where we have been and where we are going. **2012**, 1, 216-223		
450	Right ventricular dysfunction in chronic lung disease. *Cardiology Clinics*, **2012**, 30, 243-56	2.5	33
449	Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good. *Thorax*, **2012**, 67, 938-40	7.3	54
448	Sildenafil for chronic obstructive pulmonary disease: a randomized crossover trial. **2012**, 9, 268-75		68
447	Changing the idiopathic pulmonary fibrosis treatment approach and improving patient outcomes. *European Respiratory Review*, **2012**, 21, 161-7	9.8	32
446	TLR4 activity is required in the resolution of pulmonary inflammation and fibrosis after acute and chronic lung injury. **2012**, 180, 275-92		119
445	Idiopathic pulmonary fibrosis: diagnostic pitfalls and therapeutic challenges. **2012**, 7, 42		34
444	Response to pulmonary vasodilator treatment in a former smoker with combined interstitial lung disease complicated by pulmonary hypertension: case report and review of the literature. **2012**, 41, 512-7		12

443	World Health Organization Group III pulmonary hypertension. **2012**, 55, 119-27		21
442	The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis. *Respiratory Medicine*, **2012**, 106, 1447-55	4.6	66
441	Idiopathic pulmonary fibrosis: phenotypes and comorbidities. **2012**, 33, 51-7		40
440	Idiopathic pulmonary fibrosis. **2012**, 32, 473-85		6
439	[Future prospects in the treatment of idiopathic pulmonary fibrosis]. *Archivos De Bronconeumologia* , **2012**, 48 Suppl 2, 13-5	0.7	0
438	Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. *American Journal of Respiratory and Critical Care Medicine*, **2012**, 185, 1044-8	10.2	165
437	Management of idiopathic pulmonary fibrosis. **2012**, 33, 85-94		7
436	Idiopathic pulmonary fibrosis: lung function is a clinically meaningful endpoint for phase III trials. *American Journal of Respiratory and Critical Care Medicine*, **2012**, 186, 712-5	10.2	78
435	Diffuse Lung Disease. **2012**,		2
434	Gene expression profiling in the lungs of patients with pulmonary hypertension associated with pulmonary fibrosis. *Chest*, **2012**, 141, 661-673	5.3	42
433	Dyspnea in idiopathic pulmonary fibrosis: a systematic review. **2012**, 43, 771-82		55
432	Diffuse parenchymal lung disease. **2012**, 40, 314-321		5
431	Year in review 2011: acute lung injury, interstitial lung diseases, physiology, sleep and lung cancer. **2012**, 17, 554-62		1
430	Fibrocytes and the pathogenesis of diffuse parenchymal lung disease. **2012**, 5, S22		16
429	Actualitš dans la prise en charge de la fibrose pulmonaire idiopathique. **2013**, 5, 70-84		
428	Pharmacotherapy of Pulmonary Hypertension. *Handbook of Experimental Pharmacology*, **2013**,	3.2	2
427	Pulmonary hypertension in chronic lung diseases. **2013**, 62, D109-16		390
426	[French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis. From the National Reference and the Competence centers for rare diseases and the Sociť de Pneumologie de Langue Franãise]. *Revue Des Maladies Respiratoires*, **2013**, 30, 879-902	0	26

425	Acute exacerbations in patients with idiopathic pulmonary fibrosis. **2013**, 14, 86		28
424	Suspected acute exacerbation of idiopathic pulmonary fibrosis as an outcome measure in clinical trials. **2013**, 14, 73		136
423	New approaches to modulating idiopathic pulmonary fibrosis. **2013**, 13, 607-12		12
422	The evolving pharmacotherapy of pulmonary fibrosis. **2013**, 14, 79-89		19
421	Diagnostic workup for diffuse parenchymal lung disease: schematic flowchart, literature review, and pitfalls. **2013**, 191, 19-25		11
420	Pulmonary hypertension in chronic obstructive and interstitial lung diseases. **2013**, 168, 1795-804		22
419	Pulmonary hypertension due to lung disease and/or hypoxia. **2013**, 34, 695-705		26
418	Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. **2013**, 1, 369-76		276
417	Therapeutic update in idiopathic pulmonary fibrosis. **2013**, 44, 65-74		13
416	Targeted therapies for systemic sclerosis. **2013**, 9, 451-64		24
415	Referral of patients with pulmonary hypertension diagnoses to tertiary pulmonary hypertension centers: the multicenter RePHerral study. **2013**, 173, 887-93		98
414	Pathogenesis, current treatments and future directions for idiopathic pulmonary fibrosis. **2013**, 13, 377-85		66
413	Interstitial lung disease. *European Respiratory Review*, **2013**, 22, 26-32	9.8	28
412	Pulmonary Vascular Disease. **2013**, 603-625		1
411	Sildenafil preserves exercise capacity in patients with idiopathic pulmonary fibrosis and right-sided ventricular dysfunction. *Chest*, **2013**, 143, 1699-1708	5.3	149
410	Interventions to improve symptoms and quality of life of patients with fibrotic interstitial lung disease: a systematic review of the literature. *Thorax*, **2013**, 68, 867-79	7.3	74
409	Acute Exacerbation of Idiopathic Pulmonary Fibrosis: A Proposal. **2013**, 2, 233		31
408	[German guideline for diagnosis and management of idiopathic pulmonary fibrosis]. **2013**, 67, 81-111		52

407	Pharmacological treatment of idiopathic pulmonary fibrosis: from the past to the future. *European Respiratory Review*, **2013**, 22, 281-91	9.8	37
406	Treatment of pulmonary hypertension in interstitial lung disease: do not throw out the baby with the bath water. *European Respiratory Journal*, **2013**, 41, 781-3	13.6	10
405	Pulmonary hypertension and idiopathic pulmonary fibrosis: a dastardly duo. **2013**, 346, 221-5		27
404	Pulmonary hypertension in chronic interstitial lung diseases. *European Respiratory Review*, **2013**, 22, 292-301	9.8	55
403	Idiopathic pulmonary fibrosis: recent trials and current drug therapy. **2013**, 86, 353-63		26
402	Should we screen for pulmonary hypertension at the initial evaluation of idiopathic pulmonary fibrosis?. **2013**, 85, 452-5		4
401	Pulmonary hypertension in Saudi Arabia: A single center experience. **2013**, 8, 78-85		18
400	Pulmonary hypertension complicating interstitial lung disease and COPD. **2013**, 34, 600-19		16
399	Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial. *European Respiratory Journal*, **2013**, 41, 853-60	13.6	106
398	Clinical trials of idiopathic pulmonary fibrosis: choosing the (right) primary end point. **2013**, 3, 1139-1146		
397	New approaches to the design of clinical trials in idiopathic pulmonary fibrosis. **2013**, 3, 531-544		1
396	Echocardiographic and hemodynamic predictors of mortality in idiopathic pulmonary fibrosis. *Chest* , **2013**, 144, 564-570	5.3	81
395	Impact of lung transplantation on recipient quality of life: a serial, prospective, multicenter analysis through the first posttransplant year. *Chest*, **2013**, 143, 744-750	5.3	56
394	Treatment of pulmonary hypertension in idiopathic pulmonary fibrosis: shortfall in efficacy or trial design?. **2014**, 8, 875-85		19
393	Pulmonary Hypertension Associated with Respiratory Diseases. **2014**, 1-25		
392	The effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: systematic review, network meta-analysis and health economic evaluation. **2014**, 15, 63		28
391	Idiopathic Pulmonary Fibrosis Phenotypes. **2014**, 221-238		2
390	Bosentan for sarcoidosis-associated pulmonary hypertension: a double-blind placebo controlled randomized trial. *Chest*, **2014**, 145, 810-817	5.3	104

389	Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors. **2014**, 19, 700-6		27
388	Mechanisms of Fibrosis in IPF. **2014**, 161-205		5
387	Pulmonary hypertension due to fibrotic lung disease: hidden value in a neutral trial. *American Journal of Respiratory and Critical Care Medicine*, **2014**, 190, 131-2	10.2	3
386	Riociguat for pulmonary hypertension. **2014**, 7, 259-70		6
385	New therapeutic avenues for treatment of fibrosis: can we learn from other diseases?. **2014**, 32 Suppl 1, 39-49		9
384	Protocol for a mixed-methods study of supplemental oxygen in pulmonary fibrosis. **2014**, 14, 169		8
383	The burden of disease and the need for a simple staging system in idiopathic pulmonary fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2014**, 189, 765-7	10.2	4
382	Diagnosis and management of idiopathic pulmonary fibrosis: French practical guidelines. *European Respiratory Review*, **2014**, 23, 193-214	9.8	51
381	Cross-sectional assessment of the relationships between dyspnea domains and lung function in diffuse parenchymal lung disease. **2014**, 87, 105-12		7
380	Pulmonary hypertension complicating pulmonary fibrosis: bad and ugly, but good to treat?. *Thorax*, **2014**, 69, 107-8	7.3	4
379	The role of phosphodiesterase inhibitors in the management of pulmonary vascular diseases. **2014**, 2014, 257-90		10
378	Pathogenesis of idiopathic pulmonary fibrosis and its clinical implications. **2014**, 10, 1005-17		32
377	The Role of Gastroesophageal Reflux and Microaspiration in Idiopathic Pulmonary Fibrosis. **2014**, 21, 81-85		29
376	[Idiopathic pulmonary fibrosis: diagnosis and treatment in 2013]. **2014**, 70, 108-17		4
375	Diagnosis and management of interstitial lung disease. **2014**, 2, 4		88
374	Pulmonary Manifestations of Rheumatic Disease. **2014**,		2
373	Outcomes in idiopathic pulmonary fibrosis: a meta-analysis from placebo controlled trials. *Respiratory Medicine*, **2014**, 108, 376-87	4.6	56
372	Idiopathic Pulmonary Fibrosis. **2014**,		1

371	Emerging therapeutic interventions for idiopathic pulmonary fibrosis. **2014**, 23, 893-910		18
370	New therapeutic targets in idiopathic pulmonary fibrosis. Aiming to rein in runaway wound-healing responses. *American Journal of Respiratory and Critical Care Medicine*, **2014**, 190, 867-78	10.2	175
369	Review: interstitial lung disease associated with systemic sclerosis and idiopathic pulmonary fibrosis: how similar and distinct?. **2014**, 66, 1967-78		120
368	Changes in right heart haemodynamics and echocardiographic function in an advanced phenotype of pulmonary hypertension and right heart dysfunction associated with pulmonary fibrosis. *Thorax*, **2014**, 69, 123-9	7.3	47
367	[Pulmonary hypertension in chronic respiratory diseases]. **2014**, 43, 945-56		1
366	The psychometric properties of the St George Respiratory Questionnaire (SGRQ) in patients with idiopathic pulmonary fibrosis: a literature review. **2014**, 12, 124		62
365	Bosentan in pulmonary hypertension associated with fibrotic idiopathic interstitial pneumonia. *American Journal of Respiratory and Critical Care Medicine*, **2014**, 190, 208-17	10.2	116
364	Outcome of patients with severe PH due to lung disease with and without targeted therapy. **2014**, 32, 202-8		19
363	Endurance time is the most responsive exercise measurement in idiopathic pulmonary fibrosis. **2014**, 59, 1108-15		39
362	The burden of idiopathic pulmonary fibrosis: an unmet public health need. *Respiratory Medicine*, **2014**, 108, 955-67	4.6	65
361	Prevalence of overestimation or underestimation of the functional capacity using MRC score as compared to 6-minute walk test in patients with cardio-respiratory disorders. **2014**, 11, 496-502		3
360	Assessing exertional dyspnea in patients with idiopathic pulmonary fibrosis. *Respiratory Medicine*, **2014**, 108, 181-8	4.6	17
359	Idiopathic pulmonary fibrosis: evolving concepts. **2014**, 89, 1130-42		96
358	An official American Thoracic Society Statement: pulmonary hypertension phenotypes. *American Journal of Respiratory and Critical Care Medicine*, **2014**, 189, 345-55	10.2	60
357	Idiopathic pulmonary fibrosis: early detection and referral. *Respiratory Medicine*, **2014**, 108, 819-29	4.6	27
356	Pulmonary arterial hypertension treatment guidelines: new answers and even more questions. *Chest*, **2014**, 146, 239-241	5.3	5
355	Study design implications of death and hospitalization as end points in idiopathic pulmonary fibrosis. *Chest*, **2014**, 146, 1256-1262	5.3	24
354	Giants in chest medicine: Marvin I. Schwarz, MD, FCCP. *Chest*, **2014**, 145, 686-687	5.3	

353	Predicting pulmonary fibrosis disease course from past trends in pulmonary function. *Chest*, **2014**, 145, 579-585	5.3	70
352	Multi-institutional retrospective cohort study of patients with severe pulmonary hypertension associated with respiratory diseases. **2015**, 20, 805-12		28
351	Expression of mutant bone morphogenetic protein receptor II worsens pulmonary hypertension secondary to pulmonary fibrosis. **2015**, 5, 681-90		24
350	Idiopathic Pulmonary Fibrosis: Diagnosis and Clinical Manifestations. **2015**, 9, 163-71		7
349	Managing comorbidities in idiopathic pulmonary fibrosis. **2015**, 8, 309-18		27
348	Pulmonary Hypertension in Patients with Chronic Fibrosing Idiopathic Interstitial Pneumonias. **2015**, 10, e0141911		51
347	Update on diagnosis and treatment of idiopathic pulmonary fibrosis. *Jornal Brasileiro De Pneumologia*, **2015**, 41, 454-66	1.1	16
346	Pulmonary hypertension: diagnostic and therapeutic challenges. **2015**, 11, 1221-33		26
345	Update on therapeutic management of idiopathic pulmonary fibrosis. **2015**, 11, 359-70		47
344	Pharmacological Treatment of Idiopathic Pulmonary Fibrosis: Current Approaches, Unsolved Issues, and Future Perspectives. **2015**, 2015, 329481		44
343	The Challenges of Clinical Research in Orphan Diseases. **2015**, 5-15		2
342	Development of novel agents for idiopathic pulmonary fibrosis: progress in target selection and clinical trial design. *Chest*, **2015**, 148, 1083-1092	5.3	20
341	Diagnosis and Management of Pulmonary Hypertension. *Respiratory Medicine*, **2015**,	0.2	
340	Advances in the treatment of idiopathic pulmonary fibrosis. **2015**, 20, 537-52		6
339	The Idiopathic Pulmonary Fibrosis Clinical Research Network (IPFnet): diagnostic and adjudication processes. *Chest*, **2015**, 148, 1034-1042	5.3	27
338	Neue Empfehlungen bei idiopathischer Lungenfibrose. **2015**, 7, 10-11		
337	Extending the translational potential of targeting NO/cGMP-regulated pathways in the CVS. **2015**, 172, 1397-414		21
336	Pharmacologic therapies for idiopathic pulmonary fibrosis, past and future. **2015**, 47, 100-5		22

335	Pharmacological treatment of idiopathic pulmonary fibrosis: an update. **2015**, 20, 514-24		24
334	Pharmacokinetics and tolerability of oral sildenafil in adults with cystic fibrosis lung disease. **2015**, 14, 228-36		29
333	Use of pulmonary arterial hypertension-approved therapy in the treatment of non-group 1 pulmonary hypertension at US referral centers. **2015**, 5, 356-63		32
332	Update on New Treatments for Idiopathic Pulmonary Fibrosis. **2015**, 3, 134-138		
331	Hypoxic Pulmonary Hypertension. **2015**, 4169-4209		1
330	An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline. *American Journal of Respiratory and Critical Care Medicine*, **2015**, 192, e3-19	10.2	1122
329	Management of Pulmonary Hypertension in Patients with Chronic Lung Disease. **2015**, 17, 62		10
328	Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. **2015**, 3, 388-96		57
327	Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy. **2015**, 152, 18-27		61
326	Stimulators of soluble guanylate cyclase (sGC) inhibit experimental skin fibrosis of different aetiologies. **2015**, 74, 1621-5		49
325	Year in review 2014: Interstitial lung disease, physiology, sleep and ventilation, acute respiratory distress syndrome, cystic fibrosis, bronchiectasis and rare lung disease. **2015**, 20, 834-45		2
324	[3rd French day of idiopathic pulmonary fibrosis. September 19, 2014]. **2015**, 71, 189-206		
323	Acute exacerbation of idiopathic pulmonary fibrosis: shifting the paradigm. *European Respiratory Journal*, **2015**, 46, 512-20	13.6	113
322	Comorbidities in idiopathic pulmonary fibrosis patients: a systematic literature review. *European Respiratory Journal*, **2015**, 46, 1113-30	13.6	218
321	Interventional Cardiology in the Elderly. **2015**,		
320	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). *European Respiratory Journal*, **2015**, 46, 903-75	13.6	1672
319	[Dyspnea in airway and pulmonary diseases]. **2015**, 56, 882-9		3
318	Update in Pulmonary Vascular Diseases 2014. *American Journal of Respiratory and Critical Care Medicine*, **2015**, 192, 544-50	10.2	5

317	Patient considerations and drug selection in the treatment of idiopathic pulmonary fibrosis. **2016**, 12, 563-74		16
316	Pirfenidone in the treatment of idiopathic pulmonary fibrosis: an evidence-based review of its place in therapy. **2016**, 11, 11-22		46
315	The Intersection of Pulmonary Hypertension and Solid Organ Transplantation. **2016**, 12, 10-13		5
314	Traitement de la fibrose pulmonaire idiopathique : prendre en charge les symptômes. **2016**, 8, 89-91		
313	Medical Therapy in Idiopathic Pulmonary Fibrosis. **2016**, 37, 368-77		17
312	Pulmonary hypertension associated with lung diseases and hypoxemia. **2016**, 21, 299-308		6
311	Idiopathic Pulmonary Fibrosis and the Elderly: Diagnosis and Management Considerations. **2016**, 33, 321-34		24
310	Idiopathic Pulmonary Fibrosis: A Genetic Disease That Involves Mucociliary Dysfunction of the Peripheral Airways. **2016**, 96, 1567-91		126
309	Group III Pulmonary Hypertension: Pulmonary Hypertension Associated with Lung Disease: Epidemiology, Pathophysiology, and Treatments. *Cardiology Clinics*, **2016**, 34, 413-33	2.5	38
308	Under-recognised co-morbidities in idiopathic pulmonary fibrosis: A review. **2016**, 21, 995-1004		6
307	Symptom-based management of the idiopathic interstitial pneumonia. **2016**, 21, 1357-1365		20
306	Pharmacological management of IPF. **2016**, 21, 615-25		22
305	Acute and subacute idiopathic interstitial pneumonias. **2016**, 21, 810-20		33
304	Sildenafil does not Improve Exercise Capacity under Acute Hypoxia Exposure. **2016**, 37, 785-91		5
303	[Pulmonary hypertension due to chronic lung disease: Recommendations of the Cologne Consensus Conference 2016]. **2016**, 141, S57-S61		6
302	New Treatments for Idiopathic Pulmonary Fibrosis. **2016**, 23, 241-251		3
301	New insights on patient-reported outcome measures in idiopathic pulmonary fibrosis: only PROMises?. **2016**, 22, 434-41		15
300	Can sildenafil improve physical performance at altitude? Current scientific evidence. **2016**, 51, 27-35		

299	Sildenafil for pulmonary hypertension complicating idiopathic pulmonary fibrosis: a rationale grounded in basic science. *European Respiratory Journal*, **2016**, 47, 1615-7	13.6	7
298	Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report. *American Journal of Respiratory and Critical Care Medicine*, **2016**, 194, 265-75	10.2	653
297	Is there a role for sildenafil in the management of paraquat-induced lung fibrosis?. **2016**, 67, 167-8		2
296	Screening for Helicobacter pylori in Idiopathic Pulmonary Fibrosis Lung Biopsies. **2016**, 91, 3-8		18
295	Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis. *Chest*, **2016**, 149, 756-66	5.3	112
294	Targeted Therapy for Idiopathic Pulmonary Fibrosis: Where To Now?. **2016**, 76, 291-300		31
293	New perspectives on management of idiopathic pulmonary fibrosis. **2016**, 7, 108-20		24
292	Vascular effects of sildenafil in patients with pulmonary fibrosis and pulmonary hypertension: an ex vivo/in vitro study. *European Respiratory Journal*, **2016**, 47, 1737-49	13.6	23
291	Treatment of idiopathic pulmonary fibrosis: a network meta-analysis. **2016**, 14, 18		54
290	Guí ESC/ERS 2015 sobre diagnóstico y tratamiento de la hipertensió pulmonar. **2016**, 69, 177.e1-177.e62		137
289	Endothelial HIF signaling regulates pulmonary fibrosis-associated pulmonary hypertension. **2016**, 310, L249-62		47
288	Treatment of pulmonary hypertension. **2016**, 4, 323-36		75
287	Consensus document for the diagnosis and treatment of idiopathic pulmonary fibrosis: Joint Consensus of Sociedade Portuguesa de Pneumologia, Sociedade Portuguesa de Radiologia e Medicina Nuclear e Sociedade Portuguesa de Anatomia Patológica. **2016**, 22, 112-22		4
286	Update in treatment options in pulmonary hypertension. **2016**, 35, 695-703		18
285	Radiologic-pathologic discordance in biopsy-proven usual interstitial pneumonia. *European Respiratory Journal*, **2016**, 47, 1189-97	13.6	74
284	2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). **2016**, 37, 67-119		3455
283	Idiopathic Interstitial Pneumonias. **2016**, 1118-1152.e19		
282	Pulmonary Hypertension Due to Lung Disease. **2016**, 1050-1065.e5		0

281	Optimizing quality of life in patients with idiopathic pulmonary fibrosis. **2017**, 11, 157-169		49
280	Idiopathic Pulmonary Fibrosis. **2017**, 189-210		
279	Microbes Are Associated with Host Innate Immune Response in Idiopathic Pulmonary Fibrosis. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 196, 208-219	10.2	89
278	Comorbidities in interstitial lung diseases. *European Respiratory Review*, **2017**, 26,	9.8	38
277	Rheumatoid arthritis associated pulmonary hypertension: Clinical challenges reflecting the diversity of pathophysiology. **2017**, 20, 164-167		5
276	Clinical trial research in focus: why do so many clinical trials fail in IPF?. **2017**, 5, 372-374		19
275	Idiopathic Pulmonary Fibrosis: Data-driven Textural Analysis of Extent of Fibrosis at Baseline and 15-Month Follow-up. **2017**, 285, 270-278		73
274	AJRCCM: 100-Year Anniversary. Progress in Interstitial Lung Disease. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 195, 1104-1107	10.2	3
273	Idiopathic pulmonary fibrosis: Clinical behavior and aging associated comorbidities. *Respiratory Medicine*, **2017**, 129, 46-52	4.6	28
272	Predictors and Association With Clinical Outcomes of the Changes in Exercise Capacity After Transcatheter Aortic Valve Replacement. **2017**, 136, 632-643		36
271	New treatment directions for IPF: current status of ongoing and upcoming clinical trials. **2017**, 11, 533-548		9
270	[German Guideline for Idiopathic Pulmonary Fibrosis - Update on Pharmacological Therapies 2017]. **2017**, 71, 460-474		15
269	Pulmonary fibrosis, part II: state-of-the-art patient management. **2017**, 11, 361-376		6
268	Acute Exacerbation and Decline in Forced Vital Capacity Are Associated with Increased Mortality in Idiopathic Pulmonary Fibrosis. **2017**, 14, 1395-1402		71
267	Idiopathic pulmonary fibrosis. **2017**, 389, 1941-1952		617
266	Diagnostic and prognostic challenges in Idiopathic Pulmonary Fibrosis: A patient‐"Q and A" approach. *Pulmonary Pharmacology and Therapeutics*, **2017**, 42, 21-24	3.5	15
265	Idiopathic pulmonary fibrosis: lessons from clinical trials over the past 25 years. *European Respiratory Journal*, **2017**, 50,	13.6	61
264	French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis—2017 update. Full-length version. *Revue Des Maladies Respiratoires*, **2017**, 34, 900-968	0	28

263	[French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis. 2017´update. Full-length update]. *Revue Des Maladies Respiratoires*, **2017**,	0	6
262	French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis´-´2017 update. Short-length version. *Revue Des Maladies Respiratoires*, **2017**, 34, 852-899	0	2
261	[French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis: 2017 update. Short-length version]. *Revue Des Maladies Respiratoires*, **2017**,	0	
260	Severe idiopathic pulmonary fibrosis: what can be done?. *European Respiratory Review*, **2017**, 26,	9.8	23
259	Recent lessons learned in the management of acute exacerbation of idiopathic pulmonary fibrosis. *European Respiratory Review*, **2017**, 26,	9.8	39
258	Pharmacotherapy for idiopathic pulmonary fibrosis: current landscape and future potential. *European Respiratory Review*, **2017**, 26,	9.8	22
257	Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease. **2017**, 16, 755-772		146
256	Palliative care in interstitial lung disease: living well. **2017**, 5, 968-980		115
255	Idiopathic pulmonary fibrosis. **2017**, 3, 17074		395
254	Treatment of idiopathic pulmonary fibrosis in Australia and New Zealand: A position statement from the Thoracic Society of Australia and New Zealand and the Lung Foundation Australia. **2017**, 22, 1436-1458		23
253	Evaluating disease severity in idiopathic pulmonary fibrosis. *European Respiratory Review*, **2017**, 26,	9.8	40
252	Pulmonary Hypertension in Idiopathic Interstitial Pneumonias. **2017**, 103-128		
251	Pulmonary Hypertension and Interstitial Lung Disease. **2017**,		
250	Emerging therapies for idiopathic pulmonary fibrosis, a progressive age-related disease. **2017**, 16, 810		55
249	Epidemiology of Rare Lung Diseases: The Challenges and Opportunities to Improve Research and Knowledge. **2017**, 1031, 419-442		6
248	Treatment of idiopathic pulmonary fibrosis: a position paper from a Nordic expert group. **2017**, 281, 149-166		21
247	Idiopathic Pulmonary Fibrosis: The Association between the Adaptive Multiple Features Method and Fibrosis Outcomes. *American Journal of Respiratory and Critical Care Medicine*, **2017**, 195, 921-929	10.2	68
246	Pulmonary Hypertension in Diffuse Parenchymal Lung Diseases. *Chest*, **2017**, 151, 204-214	5.3	12

245	Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities. **2017**, 5, 72-84		97
244	Idiopathic interstitial pneumonia-associated pulmonary hypertension: A target for therapy?. *Respiratory Medicine*, **2017**, 122 Suppl 1, S10-S13	4.6	11
243	Comorbid Conditions in Idiopathic Pulmonary Fibrosis: Recognition and Management. *Frontiers in Medicine*, **2017**, 4, 123	4.9	47
242	Acute Exacerbation in Interstitial Lung Disease. *Frontiers in Medicine*, **2017**, 4, 176	4.9	58
241	Pulmonary Hypertension Associated with Idiopathic Pulmonary Fibrosis: Current and Future Perspectives. **2017**, 2017, 1430350		39
240	Health related quality of life in patients with idiopathic pulmonary fibrosis in clinical practice: insights-IPF registry. **2017**, 18, 139		93
239	Therapeutic effects of Saikosapoin D on bleomycininduced pulmonary fibrosis in mice via regulation of IL- 33/ST2 pathway. **2017**, 16, 581		
238	The Burden of Illness of Idiopathic Pulmonary Fibrosis: A Comprehensive Evidence Review. **2018**, 36, 779-807		38
237	Pulmonary hypertension in chronic lung diseases: comparison to other pulmonary hypertension groups. **2018**, 8, 2045894018775056		10
236	Diagnostic criteria, severity classification and guidelines of systemic sclerosis. **2018**, 45, 633-691		16
235	Sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: A Phase IIb, randomised, double-blind, placebo-controlled study - Rationale and study design. *Respiratory Medicine*, **2018**, 138, 13-20	4.6	22
234	Secondary pulmonary arterial hypertension: to treat or not to treat?. **2018**, 23, 324-329		1
233	Best supportive care for idiopathic pulmonary fibrosis: current gaps and future directions. *European Respiratory Review*, **2018**, 27,	9.8	24
232	Physiology of the lung in idiopathic pulmonary fibrosis. *European Respiratory Review*, **2018**, 27,	9.8	83
231	German Guideline for Idiopathic Pulmonary Fibrosis - Update on Pharmacological Therapies 2017. **2018**, 72, 155-168		24
230	Challenges in Pulmonary Hypertension: Controversies in Treating the Tip of the Iceberg. A Joint National Institutes of Health Clinical Center and Pulmonary Hypertension Association Symposium Report. *American Journal of Respiratory and Critical Care Medicine*, **2018**, 198, 166-174	10.2	14
229	The unmet medical need of pulmonary hypertension in idiopathic pulmonary fibrosis. *European Respiratory Journal*, **2018**, 51,	13.6	5
228	Comparative Safety of Drugs Targeting the Nitric Oxide Pathway in Pulmonary Hypertension: A Mixed Approach Combining a Meta-Analysis of Clinical Trials and a Disproportionality Analysis From the World Health Organization Pharmacovigilance Database. *Chest*, **2018**, 154, 136-147	5.3	13

227	Pulmonary hypertension in patients with interstitial lung disease. *Pulmonary Pharmacology and Therapeutics*, **2018**, 50, 38-46	3.5	13
226	Pulmonary Hypertension in Parenchymal Lung Diseases: Any Future for New Therapies?. *Chest*, **2018**, 153, 217-223	5.3	27
225	Myeloid-derived Suppressor Cells Are Necessary for Development of Pulmonary Hypertension. **2018**, 58, 170-180		19
224	The Value and Application of the 6-Minute-Walk Test in Idiopathic Pulmonary Fibrosis. **2018**, 15, 3-10		30
223	Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. **2018**, 6, 138-153		452
222	Current Trends and Future Perspectives in the Treatment of Pulmonary Hypertension: WHO Group II-V. **2018**, 43, 217-231		1
221	Models and Molecular Mechanisms of World Health Organization Group 2 to 4 Pulmonary Hypertension. **2018**, 71, 34-55		11
220	Nonpharmacologic Therapy for Idiopathic Pulmonary Fibrosis. **2018**, 65-74		
219	Triple kinase inhibitor with phosphodiesterase-5 inhibitor for idiopathic pulmonary fibrosis. *Journal of Thoracic Disease*, **2018**, 10, 5974-5978	2.6	1
218	Acute Exacerbations in Patients With Idiopathic Pulmonary Fibrosis. **2018**, 131-139		1
217	Sildenafil zum Nintedanib hat bei IPF keinen Vorteil. **2018**, 10, 18-20		
216	Management of Idiopathic Pulmonary Fibrosis. **2018**, 55-63		1
215	Utility of the six-minute walk test in patients with idiopathic pulmonary fibrosis. **2018**, 13, 45		23
214	Acute exacerbations of progressive-fibrosing interstitial lung diseases. *European Respiratory Review* , **2018**, 27,	9.8	65
213	Impact of novel antifibrotic therapy on patient outcomes in idiopathic pulmonary fibrosis: patient selection and perspectives. **2018**, 9, 321-328		20
212	Idiopathic Pulmonary Fibrosis. **2018**, 121-129		1
211	Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. *New England Journal of Medicine*, **2018**, 379, 1722-1731	59.2	135
210	Comorbidities of IPF: How do they impact on prognosis. *Pulmonary Pharmacology and Therapeutics*, **2018**, 53, 6-11	3.5	10

209	Comorbidities and Complications in Idiopathic Pulmonary Fibrosis. **2018**, 6,		12
208	Pulmonary Hypertension: Good Intentions, But a Questionable Approach. **2018**, 15, 664-666		3
207	Pulmonary Hypertension Related to Chronic Obstructive Pulmonary Disease and Diffuse Parenchymal Lung Disease: A Focus on Right Ventricular (Dys)Function. **2018**, 14, 403-411		2
206	Diagnosis and management of idiopathic pulmonary fibrosis: Thoracic Society of Australia and New Zealand and Lung Foundation Australia position statements summary. **2018**, 208, 82-88		9
205	Treating heart failure with preserved ejection fraction: learning from pulmonary fibrosis. **2018**, 20, 1385-1391		24
204	Comorbidities, Complications and Non-Pharmacologic Treatment in Idiopathic Pulmonary Fibrosis. **2018**, 6,		5
203	Management of acute respiratory failure in interstitial lung diseases: overview and clinical insights. **2018**, 18, 70		32
202	Idiopathic pulmonary fibrosis: pathogenesis and management. **2018**, 19, 32		174
201	The Efficacy and Mechanism Evaluation of Treating Idiopathic Pulmonary fibrosis with the Addition of Co-trimoxazole (EME-TIPAC): study protocol for a randomised controlled trial. **2018**, 19, 89		17
200	Associated Pulmonary Hypertension Is an Independent Contributor to Exercise Intolerance in Chronic Fibrosing Interstitial Pneumonias. **2018**, 96, 543-551		4
199	Pulmonary hypertension due to lung diseases: Updated recommendations from the Cologne Consensus Conference 2018. **2018**, 272S, 63-68		21
198	Novel management strategies for idiopathic pulmonary fibrosis. **2018**, 12, 831-842		5
197	Defining a pathological role for the vasculature in the development of fibrosis and pulmonary hypertension in interstitial lung disease. **2019**, 317, L431-L433		5
196	Acute exacerbations of idiopathic pulmonary fibrosis: Does clinical stratification or steroid treatment matter?. **2019**, 16, 1479973119869334		4
195	Chemokine signaling axis between endothelial and myeloid cells regulates development of pulmonary hypertension associated with pulmonary fibrosis and hypoxia. **2019**, 317, L434-L444		4
194	Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis and Right Heart Dysfunction. A Prespecified Subgroup Analysis of a Double-Blind Randomized Clinical Trial (INSTAGE). *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, 1505-1512	10.2	30
193	Nintedanib and Sildenafil in Patients with Idiopathic Pulmonary Fibrosis. Echoes of the Past, Lessons for the Future. *American Journal of Respiratory and Critical Care Medicine*, **2019**, 200, 1459-1461	10.2	1
192	Assessing quality of life of idiopathic pulmonary fibrosis patients: the INSTAGE study. **2019**, 15, 144-146		0

191	Real-World Comprehensive Disease Management of Patients With Idiopathic Pulmonary Fibrosis. **2019**, 15, 4-15		1
190	Pharmacotherapy and adjunctive treatment for idiopathic pulmonary fibrosis (IPF). *Journal of Thoracic Disease*, **2019**, 11, S1740-S1754	2.6	48
189	Riociguat for idiopathic interstitial pneumonia-associated pulmonary hypertension (RISE-IIP): a randomised, placebo-controlled phase 2b study. **2019**, 7, 780-790		61
188	Hypoxic Pulmonary Vasoconstriction and the Diffusing Capacity in Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis. **2019**, 8, e013310		4
187	Antifibrotic therapy for idiopathic pulmonary fibrosis: time to treat. **2019**, 20, 205		74
186	Diagnosing complications and co-morbidities of fibrotic interstitial lung disease. **2019**, 13, 645-658		7
185	Adjunctive therapies in idiopathic pulmonary fibrosis-where do we stand?. *Journal of Thoracic Disease*, **2019**, 11, 357-360	2.6	
184	Characteristics and association with survival of respiratory-related hospitalization in Japanese idiopathic pulmonary fibrosis patients. **2019**, 57, 415-421		4
183	Update in Pulmonary Fibrosis 2018. *American Journal of Respiratory and Critical Care Medicine*, **2019** , 200, 292-300	10.2	6
182	The clinical course of idiopathic pulmonary fibrosis and its association to quality of life over time: longitudinal data from the INSIGHTS-IPF registry. **2019**, 20, 59		46
181	Diagnosis and Pathophysiological Mechanisms of Group 3 Hypoxia-Induced Pulmonary Hypertension. **2019**, 21, 16		8
180	Treatment of severe idiopathic pulmonary fibrosis-is sildenafil the next (in)stage?. *Journal of Thoracic Disease*, **2019**, 11, 339-340	2.6	1
179	Guidelines for the Treatment of Pulmonary Hypertension (JCS 2017/JPCPHS 2017). **2019**, 83, 842-945		67
178	Screening Echocardiography and Brain Natriuretic Peptide Levels Predict Late Pulmonary Hypertension in Infants with Bronchopulmonary Dysplasia. **2019**, 40, 973-979		9
177	"Yap"-ing about the Antifibrotic Benefits of Prostacyclin. **2019**, 60, 499-500		2
176	Comorbidities in idiopathic pulmonary fibrosis: an underestimated issue. *European Respiratory Review*, **2019**, 28,	9.8	37
175	Phosphodiesterase 5 inhibitors for pulmonary hypertension. **2019**, 1, CD012621		32
174	Pulmonary hypertension due to interstitial lung disease. **2019**, 25, 459-467		12

173	Lung Transplantation for Interstitial Lung Disease. **2019**, 131-149		
172	Idiopathic Pulmonary Fibrosis: The Epidemiology and Natural History of Disease. *Respiratory Medicine*, **2019**, 11-35	0.2	2
171	Idiopathic Pulmonary Fibrosis for Cardiologists: Differential Diagnosis, Cardiovascular Comorbidities, and Patient Management. *Advances in Therapy*, **2019**, 36, 298-317	4.1	12
170	Interstitial Lung Disease and Other Pulmonary Manifestations in Connective Tissue Diseases. **2019**, 94, 309-325		37
169	Imatinib for right heart failure in COPD. **2019**, 9, 2045894018816974		1
168	Pulmonary Hypertension. **2019**, 327-341.e9		
167	The Hypoxic Adenosine Response and Inflammation in Lung Disease. **2019**, 23-41		
166	Pulmonary hypertension in chronic lung disease and hypoxia. *European Respiratory Journal*, **2019**, 53,	13.6	231
165	Therapeutic Options for Patients With Idiopathic Pulmonary Fibrosis. **2019**, 113-126		
164	Comorbidities and survival in patients with chronic hypersensitivity pneumonitis. **2020**, 21, 12		12
163	The Role of Palliative Care in Reducing Symptoms and Improving Quality of Life for Patients with Idiopathic Pulmonary Fibrosis: A Review. **2020**, 6, 35-46		14
162	Pulmonary hypertension secondary to pulmonary fibrosis: clinical data, histopathology and molecular insights. **2020**, 21, 303		11
161	Clinical trials in group 3 pulmonary hypertension. **2020**, 26, 391-396		3
160	Pulmonary vasculopathy in explanted lungs from patients with interstitial lung disease undergoing lung transplantation. **2020**, 7,		5
159	Health-related quality of life of patients with idiopathic pulmonary fibrosis: a systematic review and meta-analysis. *European Respiratory Review*, **2020**, 29,	9.8	4
158	The Trouble With Group 3 Pulmonary Hypertension in Interstitial Lung Disease: Dilemmas in Diagnosis and the Conundrum of Treatment. *Chest*, **2020**, 158, 1651-1664	5.3	15
157	Discovery of Novel Selective and Orally Bioavailable Phosphodiesterase-1 Inhibitors for the Efficient Treatment of Idiopathic Pulmonary Fibrosis. **2020**, 63, 7867-7879		11
156	Subtle signs - red flags. *European Respiratory Journal*, **2020**, 55,	13.6	1

155	Cardiac Considerations in Chronic Lung Disease. *Respiratory Medicine*, **2020**,	0.2	0
154	The importance of interventional timing in the bleomycin model of pulmonary fibrosis. *European Respiratory Journal*, **2020**, 55,	13.6	27
153	Development and Initial Validation Analyses of the Living with Idiopathic Pulmonary Fibrosis Questionnaire. *American Journal of Respiratory and Critical Care Medicine*, **2020**, 202, 1689-1697	10.2	9
152	Design, synthesis and discovery of 2(1H)-quinolone derivatives for the treatment of pulmonary fibrosis through inhibition of TGF-β/smad dependent and independent pathway. **2020**, 197, 112259		3
151	Chronic lung disease-associated PH: PAH-approved drugs and established universal healthcare insurance in Japan. **2020**, 58, 230-231		
150	Acute Exacerbation of Idiopathic Pulmonary Fibrosis. **2020**,		1
149	Idiopathic pulmonary fibrosis and pulmonary hypertension: Heracles meets the Hydra. **2021**, 178, 172-186		7
148	Targeting the NO-cGMP-PDE5 pathway in COVID-19 infection. The DEDALO project. **2021**, 9, 33-38		26
147	Standardization of the 6-min walk test in clinical trials of idiopathic pulmonary fibrosis. **2021**, 100, 106227		1
146	NO-sensitive guanylyl cyclase in the lung. **2020**,		1
145	Efficacy and safety of sildenafil added to pirfenidone in patients with advanced idiopathic pulmonary fibrosis and risk of pulmonary hypertension: a double-blind, randomised, placebo-controlled, phase 2b trial. **2021**, 9, 85-95		33
144	The Challenge to Decide between Pulmonary Hypertension Due to Chronic Lung Disease and PAH with Chronic Lung Disease. *Diagnostics*, **2021**, 11,	3.8	3
143	Pulmonary Hypertension Associated With Respiratory Diseases - Which Patients Should Be Treated With Pulmonary Arterial Hypertension-Targeted Therapies?. **2021**, 85, 343-344		
142	Blood Transcriptomics Predicts Progression of Pulmonary Fibrosis and Associated Natural Killer Cells. *American Journal of Respiratory and Critical Care Medicine*, **2021**, 204, 197-208	10.2	7
141	Group 3 Pulmonary Hypertension: A Review of Diagnostics and Clinical Trials. **2021**, 42, 59-70		3
140	Pharmacological treatment of idiopathic pulmonary fibrosis and fibrosing interstitial lung diseases: current trends and future directions. **2021**, 5, 31-40		
139	Parenteral prostanoids for severe Group 3 pulmonary hypertension with right ventricular dysfunction. *Journal of Thoracic Disease*, **2021**, 13, 1466-1475	2.6	
138	Significance of autoimmune disease in severe pulmonary hypertension complicating extensive pulmonary fibrosis: a prospective cohort study. **2021**, 11, 20458940211011329		3

137	Idiopathic pulmonary fibrosis beyond the lung: understanding disease mechanisms to improve diagnosis and management. **2021**, 22, 109		11
136	Drug Repurposing Approach, Potential Drugs, and Novel Drug Targets for COVID-19 Treatment. **2021**, 2021, 6631721		11
135	Treatment of chronic fibrosing interstitial lung diseases. **2021**, 64, 277-285		
134	Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here?. *European Respiratory Review*, **2021**, 30,	9.8	2
133	The impact of idiopathic pulmonary fibrosis on health state utility values: evidence from Australia. **2021**, 30, 2615-2632		1
132	Pulmonary hypertension in interstitial lung disease: screening, diagnosis and treatment. **2021**, 27, 396-404		4
131	Die idiopathische pulmonale Fibrose jenseits der Lunge: Krankheitsmechanismen verstehen, um Diagnose und Therapie zu verbessern. 1-12		
130	Management of Pulmonary Hypertension Due to Chronic Lung Disease. **2021**, 17, 124-133		
129	Right ventricular contractility decreases during exercise in patients with non-advanced idiopathic pulmonary fibrosis. **2021**, 100, e25915		
128	Shifting gears: the search for group 3 pulmonary hypertension treatment. **2021**, 27, 296-302		1
127	Co-trimoxazole to reduce mortality, transplant, or unplanned hospitalisation in people with moderate to very severe idiopathic pulmonary fibrosis: the EME-TIPAC RCT. **2021**, 8, 1-110		
126	Vaso reactivity test using inhaled nitric oxide for pulmonary arterial hypertension accompanied by severe interstitial lung disease attributed to systemic sclerosis: A case report.. **2022**, 25, 144-148		
125	An updated approach to determine minimal clinically important differences in idiopathic pulmonary fibrosis. *ERJ Open Research*, **2021**, 7,	3.5	1
124	Effect of sildenafil added to antifibrotic treatment in idiopathic pulmonary fibrosis. **2021**, 11, 17824		3
123	Pulmonary hypertension in fibrosing idiopathic interstitial pneumonia: Uncertainties, challenges and opportunities. **2021**, 40, 872-881		0
122	An IPF-like disease course in disorders other than IPF: how can this be anticipated, recognized, and managed?. **2021**, 17, 1091-1101		1
121	Management of Acute Exacerbation of Idiopathic Pulmonary Fibrosis in Specialised and Non-specialised ILD Centres Around the World. *Frontiers in Medicine*, **2021**, 8, 699644	4.9	3
120	A Comprehensive Guide to Lung Transplantation for the Recipient With Pulmonary Fibrosis. **2022**, 661-675		

119	Group 3 PH: Clinical Features and Treatment. **2022**, 678-690		
118	Idiopathic Pulmonary Fibrosis-Treatment and Management. **2022**, 218-233		
117	Common Co-Morbidities in Fibrosing Interstitial Lung Disease. **2022**, 79-87		
116	Lung Transplantation for Pulmonary Hypertension. **2022**, 650-660		
115	Symptom Management in Advanced Lung Disease. *Respiratory Medicine*, **2021**, 135-145	0.2	
114	Phase three clinical trials in idiopathic pulmonary fibrosis. **2021**, 9, 1-11		0
113	Acute Exacerbation of Idiopathic Pulmonary Fibrosis. **2014**, 349-362		1
112	Idiopathic Pulmonary Fibrosis: The Epidemiology and Natural History of Disease. **2014**, 9-34		1
111	Pulmonary Hypertension Associated with Chronic Lung Diseases: Treatment Considerations. *Respiratory Medicine*, **2020**, 79-96	0.2	1
110	Clinical Trials in IPF: What Are the Best Endpoints?. *Respiratory Medicine*, **2019**, 433-453	0.2	2
109	Therapeutics targeting of dysregulated redox equilibrium and endothelial dysfunction. *Handbook of Experimental Pharmacology*, **2013**, 218, 315-49	3.2	10
108	Evolution and treatment of idiopathic pulmonary fibrosis. **2020**, 49, 104025		6
107	Pharmacological and nonpharmacological interventions to improve symptom control, functional exercise capacity and quality of life in interstitial lung disease: an evidence synthesis. *ERJ Open Research*, **2021**, 7,	3.5	3
106	Pharmacological management. 196-217		1
105	Progression of fibrosing interstitial lung disease. **2020**, 21, 32		39
104	Recent advances in managing idiopathic pulmonary fibrosis. **2017**, 6, 2052		9
103	The treatment of idiopathic pulmonary fibrosis. **2014**, 6, 16		43
102	Adverse events of pirfenidone for the treatment of pulmonary fibrosis: a meta-analysis of randomized controlled trials. **2012**, 7, e47024		41

101	Riociguat versus sildenafil on hypoxic pulmonary vasoconstriction and ventilation/perfusion matching. **2018**, 13, e0191239		10
100	Pulmonary Hypertension in Idiopathic Pulmonary Fibrosis. *Advances in Pulmonary Hypertension*, **2013**, 12, 127-134	0.5	1
99	Pulmonary Hypertension.		12
98	Pulmonary Hypertension. **2017**, 114, 73-84		57
97	The clinical effectiveness and cost-effectiveness of treatments for idiopathic pulmonary fibrosis: a systematic review and economic evaluation. **2015**, 19, i-xxiv, 1-336		19
96	The Clinical Efficacy of Pulmonary Hypertension-Specific Agents in Idiopathic Pulmonary Fibrosis: Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials. *Journal of Korean Medical Science*, **2020**, 35, e48	4.7	4
95	Brazilian guidelines for the pharmacological treatment of idiopathic pulmonary fibrosis. Official document of the Brazilian Thoracic Association based on the GRADE methodology. *Jornal Brasileiro De Pneumologia*, **2020**, 46, e20190423	1.1	2
94	A review of current and novel therapies for idiopathic pulmonary fibrosis. *Journal of Thoracic Disease*, **2013**, 5, 48-73	2.6	93
93	Acute exacerbation of idiopathic pulmonary fibrosis-a review of current and novel pharmacotherapies. *Journal of Thoracic Disease*, **2015**, 7, 499-519	2.6	54
92	Phosphodiesterase Type 5 Inhibitors and COVID-19: Are They Useful In Disease Management?. *World Journal of Men?s Health*, **2020**, 38, 254-255	6.8	8
91	Dominating Cause of Pulmonary Hypertension May Change Over Time-Diagnostic and Therapeutic Considerations in a Patient with Pulmonary Hypertension Due to Rheumatoid Arthritis with Lung Involvement. *Diagnostics*, **2021**, 11,	3.8	0
90	Connective Tissue Disease, Interstitial Lung Disease, and Pulmonary Hypertension (CTD PH-ILD): A Distinct Entity and Potential Opportunity. *Advances in Pulmonary Hypertension*, **2021**, 20, 109-118	0.5	
89	Management of PH-ILD: Past, Present, and Future. *Advances in Pulmonary Hypertension*, **2021**, 20, 119-122	0.5	0
88	Health Related Quality of Life in Interstitial Lung Disease: Can We Use the Same Concepts Around the World?. *Frontiers in Medicine*, **2021**, 8, 745908	4.9	
87	Antihypertonika. **2011**, 401-420		
86	Interstitial Lung Disease. *Tuberculosis and Respiratory Diseases*, **2011**, 71, 163	3.2	
85	Pulmonary Hypertension in Interstitial Lung Disease. **2012**, 121-135		
84	Interstitial Lung Disease. **2012**, 556-567		0

83	Screening for Pulmonary Arterial Hypertension. *Advances in Pulmonary Hypertension*, **2012**, 11, 78-83	0.5	1
82	Right Heart Failure. **2014**, 311-329		
81	Pharmacological Treatment of Idiopathic Pulmonary Fibrosis. **2014**, 297-311		
80	Idiopathic Pulmonary Fibrosis Clinical Trials: Evolving Concepts. **2014**, 403-426		
79	Current and Emerging Treatment Options in Interstitial Lung Disease. **2014**, 193-216		
78	Hypoxic Pulmonary Hypertension. **2014**, 1-49		
77	Hypoxic Pulmonary Hypertension. *Respiratory Medicine*, **2015**, 67-92	0.2	
76	Pulmonary Hypertension in the Elderly: Impact of Age on Diagnosis and Therapy Options. **2015**, 109-133		
75	Antihypertonika. **2015**, 451-475		
74	Pulmonary Hypertension Associated with Respiratory Disease. **2015**, 4211-4231		
73	Pulmonary Hypertension in Patients Without Pulmonary Arterial Hypertension. **2016**, 29-61		
72	Antihypertonika. **2016**, 335-350		
71	"A small leak will sink a great ship": hypoxia-inducible factor and group III pulmonary hypertension. *Receptors & Clinical Investigation*, **2016**, 3,		2
70	Investigative Approaches to Drug Therapy. **2017**, 583-594		
69	Non-Group 1 Pulmonary Hypertension Associated With Systemic Sclerosis: An Under-studied Patient Population. *Advances in Pulmonary Hypertension*, **2017**, 16, 68-75	0.5	
68	Pathology of Vascular Changes in Interstitial Lung Diseases. **2017**, 45-66		
67	Antihypertonika. **2017**, 335-351		
66	Treatment of Pulmonary Hypertension in Interstitial Lung Disease. **2017**, 67-84		

65	. *Praxis*, **2017**, 106, 999-1006	0.1	
64	Antihypertonika. **2018**, 385-400		
63	Acute exacerbation of idiopathic pulmonary fibrosis. *Pulmonologiya*, **2018**, 28, 469-482	0.8	0
62	Acute Exacerbation of Idiopathic Pulmonary Fibrosis. *Respiratory Medicine*, **2019**, 401-417	0.2	1
61	Pharmacologic Treatment of IPF. *Respiratory Medicine*, **2019**, 325-364	0.2	1
60	Gastroesophageal Reflux and IPF. *Respiratory Medicine*, **2019**, 379-387	0.2	
59	Cardiovascular implications of pulmonary hypertension due to chronic respiratory diseases. **2020**, 167-183		
58	Identification of the Molecular Basis of Anti-fibrotic Effects of Soluble Guanylate Cyclase Activator Using the Human Lung Fibroblast Phosphoproteome.		1
57	ERKRANKUNGEN DER ATMUNGSORGANE. **2020**, C-1-C22-4		
56	Acute exacerbations. 143-150		0
55	Pulmonary hypertension. 160-174		
54	Symptom management: dyspnoea and cough. 218-229		
53	Phosphodiesterase-5 inhibitors. *Handbook of Experimental Pharmacology*, **2013**, 218, 229-55	3.2	2
52	The association between health-related quality of life and disease progression in idiopathic pulmonary fibrosis: a prospective cohort study. *Sarcoidosis Vasculitis and Diffuse Lung Diseases*, **2017**, 34, 226-235	1.1	1
51	Management of interstitial lung diseases: A consensus statement of the Indian Chest Society (ICS) and National College of Chest Physicians (NCCP). *Lung India*, **2020**, 37, 359-378	1.1	1
50	Lung Disease-Related Pulmonary Hypertension. *Cardiology Clinics*, **2022**, 40, 77-88	2.5	
49	Survival of patients with idiopathic pulmonary fibrosis and pulmonary hypertension under therapy with nintedanib or pirfenidone. *Internal and Emergency Medicine*, **2021**,	3.7	0
48	The psychometric properties of the King© Brief Interstitial Lung Disease questionnaire and thresholds for meaningful treatment response in patients with progressive fibrosing interstitial lung diseases. *European Respiratory Journal*, **2021**,	13.6	0

47	Management of interstitial lung diseases: A consensus statement of the Indian Chest Society (ICS) and National College of Chest Physicians (NCCP). *Lung India*, **2020**, 37, 359	1.1	3
46	Inhaled Treprostinil in PH-ILD - A Success, Finally. *American Journal of Respiratory and Critical Care Medicine*, **2021**,	10.2	1
45	Pulmonary Hypertension in Interstitial Lung Disease.. *Archivos De Bronconeumologia*, **2022**,	0.7	
44	Medical treatments for idiopathic pulmonary fibrosis: a systematic review and network meta-analysis.. *Thorax*, **2022**,	7.3	3
43	Vardenafil Activity in Lung Fibrosis and In Vitro Synergy with Nintedanib.. *Cells*, **2021**, 10,	7.9	0
42	Screening Strategies for Pulmonary Hypertension in Patients with Interstitial Lung Disease: A Multidisciplinary Delphi Study.. *Chest*, **2022**,	5.3	2
41	THE TRANSLATIONAL POSSIBILITY OF TARGETING LncRNAs AS A THERAPEUTIC STRATEGY FOR IDIOPATHIC PULMONARY FIBROSIS. *Asian Journal of Pharmaceutical and Clinical Research*, 13-20	0.4	
40	Clinical outcomes of sildenafil application in patients of poor endometrial development. *Gynecology and Obstetrics Clinical Medicine*, **2022**, 2, 14-19		
39	Practical considerations in the management of inhaled prostacyclin therapy for pulmonary hypertension associated with interstitial lung disease (WHO group 3).. *Respiratory Medicine*, **2022**, 196, 106806	4.6	
38	Sildenafil for idiopathic pulmonary fibrosis: A systematic review and meta-analysis.. *Pulmonary Pharmacology and Therapeutics*, **2022**, 73-74, 102128	3.5	0
37	Interstitielle Lungenerkrankungen. **2022**, 92-102		
36	Group 3 Pulmonary Hypertension: From Bench to Bedside.. *Circulation Research*, **2022**, 130, 1404-1422	15.7	1
35	Heart failure. **2013**, 169-223		5
34	Ongoing Clinical Trials in Aging-Related Tissue Fibrosis and New Findings Related to AhR Pathways. **2022**, 13, 732		0
33	ERS International Congress 2021: highlights from the Pulmonary Vascular Diseases Assembly. *ERJ Open Research*, **2022**, 8, 00665-2021	3.5	0
32	Discovery of Dipyridamole Analogues with Enhanced Metabolic Stability for the Treatment of Idiopathic Pulmonary Fibrosis. *Molecules*, **2022**, 27, 3452	4.8	
31	Recommandations pratiques pour le diagnostic et la prise en charge de la fibrose pulmonaire idiopathique TActualisation 2021. Version intgrale. *Revue Des Maladies Respiratoires*, **2022**,	0	
30	Clinical Assessment for Pulmonary Hypertension in Interstitial Lung Disease. *Internal Medicine Journal*,	1.6	

29	The Antifibrotic Effects of Inhaled Treprostinil: An Emerging Option for ILD. *Advances in Therapy*,	4.1	0
28	Recent advances in the management of pulmonary hypertension with interstitial lung disease. *European Respiratory Review*, **2022**, 31, 210220	9.8	2
27	Clinical significance of pulmonary hypertension in interstitial lung disease: A consensus statement from the Pulmonary Vascular Research Institute innovative drug development initiative roup 3 pulmonary hypertension. **2022**, 12,		2
26	2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. 2200879		18
25	French practical guidelines for the diagnosis and management of idiopathic pulmonary fibrosis - 2021 update. Full-length version. **2022**, 100948		
24	2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension.		58
23	Pulmonary Hypertension in Interstitial Lung Disease: An area of unmet clinical need. 00272-2022		1
22	Syndrome of Combined Pulmonary Fibrosis and Emphysema: An Official ATS/ERS/JRS/ALAT Research Statement. **2022**, 206, e7-e41		3
21	The 6-min walk test as a primary end-point in interstitial lung disease. **2022**, 31, 220087		0
20	Chitinase 3-like-1 contributes to the development of pulmonary vascular remodeling in pulmonary hypertension.		0
19	Phosphodiesterase 5 inhibitor treatment and survival in interstitial lung disease pulmonary hypertension: A Bayesian retrospective observational cohort study.		1
18	Critical Care of the Lung Transplant Patient. **2022**, 43, 457-470		0
17	Strategizing Drug Therapies in Pulmonary Hypertension for Improved Outcomes. **2022**, 15, 1242		2
16	PDE5 to keep them alive: The use of phosphodiesterase type-5 inhibitors in severe pulmonary hypertension associated with interstitial lung disease.		0
15	Management of Interstitial Lung Diseases: A Consensus Statement of the Indian Chest Society and National College of Chest Physicians (India). **2022**, 62, 73-98		0
14	The estimation of health state utility values in rare diseases: do the approaches in submissions for NICE technology appraisals reflect the existing literature? A scoping review.		0
13	Consensus Statement for the Diagnosis and Treatment of Idiopathic Pulmonary Fibrosis in Resource Constrained Settings. **2022**, 60, 91-119		0
12	Pulmonary hypertension in interstitial lung disease: Clinical trial design and endpoints: A consensus statement from the Pulmonary Vascular Research Institute Innovative Drug Development Initiative roup 3 Pulmonary Hypertension. **2022**, 12,		0

11	Diagnosis and management of pulmonary hypertension related to chronic respiratory disease. **2022**, 18, 220205	0
10	Tensions in Taxonomies: Current Understanding and Future Directions in the Pathobiologic Basis and Treatment of Group 1 and Group 3 Pulmonary Hypertension. 4295-4319	0
9	Idiopathic pulmonary fibrosis: state of the art for 2023. **2023**, 61, 2200957	0
8	Trials and Treatments: An Update on Pharmacotherapy for Idiopathic Pulmonary Fibrosis. **2023**, 13, 486	0
7	Pharmakotherapie der idiopathischen Lungenfibrose (ein Update) und anderer progredienter pulmonaler Fibrosen. **2023**, 77, 94-119	1
6	Diagnosis and Pharmacologic Management of Fibrotic Interstitial Lung Disease. **2023**, 13, 599	0
5	Case report: High-dose epoprostenol therapy in pediatric patients with pulmonary hypertension and developmental lung disease. 11,	0
4	Pharmacology and Emerging Therapies for Group 3 Pulmonary Hypertension Due to Chronic Lung Disease. **2023**, 16, 418	0
3	New 6-Minute-Walking Test Parameter Distance/Desaturation Index (DDI) Correctly Diagnoses Short-Term Response to Immunomodulatory Therapy in Hypersensitivity Pneumonitis. **2023**, 13, 1109	0
2	Thalidomide interaction with inflammation in idiopathic pulmonary fibrosis.	0
1	The Syndrome of Combined Pulmonary Fibrosis and Emphysema. **2023**, 561-588	0